| Trial ID: | L4854 |
| Source ID: | NCT06613750
|
| Associated Drug: |
Sitagliptin And Gliclazide
|
| Title: |
Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity
|
| Acronym: |
SG Metformin
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus|Glucotoxicity
|
| Interventions: |
DRUG: Sitagliptin and Gliclazide|DRUG: Metformin
|
| Outcome Measures: |
Primary: Change in Glycated Hemoglobin (HbA1c) Levels from Baseline to 12 Weeks, This outcome measures the change in HbA1c levels in participants over a 12-week period, comparing sitagliptin and gliclazide treatments with metformin for type 2 diabetes mellitus patients with glucotoxicity., 12 weeks | Secondary: Change in Fasting Plasma Glucose (FPG) and Body Mass Index (BMI), Secondary outcomes include changes in FPG, BMI, and the proportion of participants achieving FPG levels below 6.1 mmol/L and 7.2 mmol/L after 12 weeks of treatment., 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Zhibin Xu | Collaborators: Nanfang Hospital, Southern Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
129
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-06-01
|
| Completion Date: |
2024-07-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-09-26
|
| Locations: |
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510120, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06613750
|
